Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEland Oil & Gas Regulatory News (ELA)

  • There is currently no data for ELA

Operations Update

30 Oct 2019 07:00

RNS Number : 5460R
Eland Oil & Gas PLC
30 October 2019
 

30 October 2019

Eland Oil & Gas PLC

("Eland" or the "Company")

Operations Update

 

 

Eland Oil & Gas PLC (AIM: ELA), an oil & gas production and development company operating in West Africa with an initial focus on Nigeria, announces that through its joint-venture subsidiary, Elcrest Exploration and Production Nigeria Ltd ("Elcrest"), it has suspended completion operations on its Gbetiokun-4 production well due to technical issues.

 

Gbetiokun-4

The Gbetiokun-4 development well drilled through 345 net feet true vertical depth ('TVD') of oil-bearing sand, successfully recovered 60ft of core in the E5.0 reservoir and encountered each of its three target reservoirs (E3.0, E5.0 and E7.0) oil filled and close to or better than prognosed in terms of depth and quality. The well reached a Total Depth of 10,083 ft TVD and following a successful open-hole logging campaign, the 9-5/8" casing was successfully installed.

 

After cementing the 9-5/8" casing and perforating the E3.0, E5.0 and E7.0 sands, the dual 3.5" completion, comprising a single packer and two dual packers, was installed. After setting the packer in the long string to isolate the E7.0 sand, attempts were made to set the two dual packers via the short string, to isolate the E3.0 and E5.0 sands. This was unsuccessful and during further attempts to set the dual packers one, or more, components in the short string failed and the required packer setting pressure could not be achieved. After completing diagnostic tests, it was determined the completion had to be retrieved to replace the failed component(s).

 

Operations to retrieve the completion have been ongoing. However, so far, only partial retrieval has been achieved. To complete the operation additional equipment and resources are required that are not currently available in-country and therefore the decision has been taken to suspend operations while they are sourced.

 

Moving forward, the OES Teamwork rig will suspend the Gbetiokun-4 well to make it safe and move to an adjacent slot to commence operations on the next planned development well, Gbetiokun-5. This is expected to be spudded in the next 2 weeks.

 

Once the identified equipment and personnel are obtained, a decision on the timing of re-entering Gbetiokun-4 will be finalised. The re-entry may involve use of a dedicated hydraulic workover unit ('HWU') rather than a drill rig. Once the remaining completion equipment is recovered, it is anticipated that a new completion will be installed and the well brought into production shortly thereafter.

 

Ubima Marginal Field

 

The planned Extended Well Tested ('EWT') of the E1.0/E2.0 reservoirs in the Ubima-1 well has experienced delays due to various permitting issues that the field Operator is working to resolve. Currently this EWT is still anticipated to commence in Q4 2019, but likely not before mid-November.

 

 

Revised 2019 Production Guidance

 

Despite a successful intervention on the Opuama-9 short string during Q3, the extended drilling operations and current non-completion of Gbetiokun-4, the associated delay to the Gbetiokun-5 production well and the delayed start of the Ubima EWT have a cumulative negative impact on the previous 2019 production guidance (12,000-13,500 bopd net). Based on current assumptions for both Gbetiokun drilling operations and the Ubima EWT we expect full year production to be approximately 10,500 bopd net.

 

 

George Maxwell, CEO of Eland, commented:

 

"The challenges on Gbetiokun-4 highlight the complexities that can occur in the drilling and completion sequence. Over the past three years we have successfully overcome these types of equipment challenges during our ongoing drilling campaign and we are confident that when the required equipment arrives in country, we will move forward with the completion of Gbetiokun-4 and bring further production online as planned.

 

The production delay is clearly disappointing. However, with the excellent reservoir results witnessed while drilling we anticipate strong production performance from Gbetiokun-4 once online. Moving the rig on to Gbetiokun-5 while awaiting the arrival of required Gbetiokun-4 completion equipment is the most efficient move at this time and continues the drive towards increased production on Gbetiokun."

 

 

 

For further information:

 

Eland Oil & Gas PLC (+44 (0)1224 737300)

www.elandoilandgas.com

George Maxwell, CEO

Ronald Bain, CFO

Finlay Thomson, IR

 

Peel Hunt LLP, Nominated Adviser & Joint Broker (+44 (0)20 7418 8900)

Richard Crichton

David McKeown

 

Stifel Nicolaus Europe Limited, Joint Broker (+44 (0)20 7710 7600)

Callum Stewart

Nicholas Rhodes

Ashton Clanfield

 

Camarco (+44 (0) 203 757 4980)

Billy Clegg

Tom Huddart

Monique Perks

 

In accordance with the guidelines of the AIM Market of the London Stock Exchange, Yannis Korakakis, MSc of Leoben University, with 32 years of experience in the oil and gas sector, is a Petroleum Engineer and member of the Society of Petroleum Engineers who meets the criteria of qualified persons under the AIM guidance note for mining and oil and gas companies, has reviewed and approved the technical information contained in this announcement.

This announcement contains inside information as defined in Article 7 of the Market Abuse Regulation No. 596/2014 and is disclosed in accordance with the Company's obligations under Article 17 of those Regulations.

This announcement is available on Eland's website at www.elandoilandgas.com/investors/regulatory-news/. The content of Eland's website is not incorporated into, nor does it form part of, this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDGMMZGZLMGLZZ
Date   Source Headline
17th Jul 20095:57 pmBUSStudies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimer's Disease
16th Jul 20092:18 pmRNSResults of Annual General Meeting
13th Jul 200911:30 amBUSElan and Transition Therapeutics Announce Phase 1 Data Showing ELND005 Achieves Desired Concentrations in Brain Tissue and Cerebrospinal Fluid
10th Jul 20094:59 pmRNSCancellation of UK Listing
8th Jul 20097:00 amBUSElan Announces Webcast of Second Quarter 2009 Financial Results
3rd Jul 200910:57 amRNSBlock Listing Six Monthly Return
2nd Jul 200912:57 pmRNSHolding in Company
2nd Jul 200912:41 pmPRNJohnson & Johnson, Elan Announce Definitive Agreement
1st Jun 20097:00 amBUSSubset Data from Two Randomized Phase 3 Trials Show TYSABRI® Significantly Improves Health-Related Quality of Life for Crohn's Disease Patients with Prior Exposure or Inadequate Response to Anti-TNF? Therapy
29th May 20094:36 pmRNSPrice Monitoring Extension
29th May 20092:00 pmBUSRenee P. Tannenbaum, Pharm.D. Joins Elan as Executive Vice President and Chief Commercial Officer
29th May 200911:54 amBUSTotal Voting Rights
30th Apr 200912:16 pmBUSTotal Voting Rights
27th Apr 20093:35 pmRNSAnnual Report
14th Apr 20095:09 pmRNSHolding(s) in Company
27th Feb 20092:44 pmBUSTotal Voting Rights
25th Feb 200912:23 pmBUSDirector/PDMR Shareholding
12th Feb 20096:00 pmBUSDirector/PDMR Shareholding
12th Feb 20096:00 pmBUSDirector/PDMR Shareholding
9th Feb 20097:00 amBUSMS Patients Treated with TYSABRI® Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology
4th Feb 20092:32 pmRNSHolding(s) in Company
3rd Feb 20093:57 pmRNSHolding(s) in Company
30th Jan 20094:33 pmRNSHolding(s) in Company
28th Jan 20094:24 pmRNSHolding(s) in Company
13th Jan 20097:00 amBUSElan Clarifies Duration of Bapineuzumab Phase 3 Trials
12th Jan 20095:21 pmRNSHolding(s) in Company
12th Jan 20097:00 amBUSTysabri Update
2nd Jan 200912:21 pmRNSTotal Voting Rights
18th Dec 20084:24 pmRNSBlock Listing Six Monthly Return
16th Dec 200811:00 amBUSDirector Declaration
16th Dec 20087:00 amBUSElan to Present at the 27th Annual JP Morgan Healthcare Conference
15th Dec 20083:02 pmBUSTysabri Update
12th Dec 20087:00 amBUSElan Announces Resource Realignment
28th Nov 200810:47 amBUSTotal Voting Rights
25th Nov 20087:00 amBUSMary Stutts to Join Elan as Senior Vice President and Head of Corporate Relations
20th Nov 20087:00 amBUSCarlos V. Paya, MD, PhD, to Join Elan as Company President
3rd Nov 20085:12 pmRNSDirector/PDMR Shareholding
31st Oct 20084:11 pmRNSHolding in Company
31st Oct 200812:01 pmRNSTotal Voting Rights
30th Oct 20084:13 pmRNSTysabri Update
3rd Oct 20085:56 pmRNSHolding in Company
30th Sep 20084:11 pmRNSTotal Voting Rights
22nd Sep 200811:26 amRNSHolding In Company
22nd Sep 20087:00 amRNSTysabri Demonstrates Sustained Improvement
11th Sep 20087:39 amRNSDirector /PDMR Shareholding
1st Sep 20085:02 pmRNSHolding(s) in Company
29th Aug 200810:54 amRNSTotal Voting Rights
28th Aug 20087:00 amRNSInterim Results
14th Aug 20084:12 pmRNSHolding in Company
13th Aug 20085:22 pmRNSHolding in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.